Feature | December 15, 2014

St. Joseph's Children's Hospital Implants 50th Pulmonary Valve Without Open-Heart Surgery

Facility is highest-volume Melody valve implanting center in Florida, one of the busiest in the United States

December 15, 2014 — Doctors at St. Joseph’s Children’s Hospital of Tampa implanted a Melody transcatheter pulmonary valve in a 13-year-old patient in October, marking the 50th time the hospital has given the device to a patient.

Thirteen-year-old Cyrus Yarley was born with multiple heart defects and underwent open-heart surgery at just 1 week old then again at age 8. His mother, Valorie Daniels, knew the day would come when Cyrus would need to have his pulmonary valve replaced, and had anticipated another open-heart surgery for the past five years. Use of the Melody valve, however, precluded the need for an additional incision. After inserting a catheter into a vein in the upper leg, pediatric cardiologist Jeremy Ringewald, M.D., guided the Melody valve up to Cyrus' heart and replaced his current dysfunctional pulmonary valve

The Melody valve from Medtronic replaces narrow or leaky pulmonary valve conduits in children or adults who have previously undergone congenital heart surgery. St. Joseph's Children's Hospital is the highest-volume Melody valve implanting center in Florida and one of the busiest in the United States.

"Children born with blocked or leaky heart valves usually undergo multiple open-heart surgeries before reaching adulthood to replace conduits that have worn out or that they have outgrown," said Ringewald. "This groundbreaking technology can markedly prolong the time between surgeries for many patients, with the goal of maximizing heart health and minimizing invasiveness."

According to Ringewald, the Melody valve procedure is typically performed under general anesthesia in less than four hours. Unlike open-heart surgical procedures, where the hospital stay is approximately a week, patients are usually discharged from the hospital within 24 hours. 

While Melody valve therapy cannot be used in all cases of abnormal pulmonary valve function, it can give doctors an alternative to repeated traditional open-heart procedures, offering children and adults who may not be able to tolerate another open-heart surgery hope for the future.

For more information: www.medtronic.com

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init